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Summary
 
Context 
 
The role of somatostatin analogues (SSTa) in the treat-
ment of acromegaly.
 
Objective 
 
To  evaluate the antihormonal and antitumour efﬁcacy
of long-term (up to 18  years) primary treatment with SSTa in
patients with GH-secreting pituitary adenoma responsive to SSTa.
 
Design 
 
An open, prospective, single-centre, clinical study.
 
Patients 
 
Thirty-six acromegalic patients, aged 17–75 years (postoral
glucose tolerance test GH 
 
>
 
 1 
 
µ
 
g/l, increased IGF-1 for age and
sex), were monitored in a single centre and treated with SSTa as ﬁrst-
line therapy. The mean pretreatment GH level was 13·5 
 
±
 
 3·1 
 
µ
 
g/l,
and IGF-1 (as a percentage of the value over the normal range) was
302 
 
±
 
 26%. The patients had macroadenoma (
 
n
 
 
 
=
 
 25), micro-
adenoma (
 
n
 
 
 
=
 
 8) or empty sella turcica (
 
n
 
 
 
=
 
 3). The mean duration of
treatment was 8 years (range 3–18 years). Hormonal and morpho-
logical monitoring was undertaken after 6 months, and then the
patients were followed annually.
 
Results 
 
After 1 year, the mean GH and IGF-1 levels had reduced
considerably (GH: 2·4 
 
±
 
 0·3 
 
µ
 
g/l; IGF-1; 174 
 
±
 
 14%, 
 
P
 
 
 
<
 
 0·01), and
they continued to decrease over 10 years, with a mean GH level of
1·6 
 
±
 
 0·1 
 
µ
 
g/l and IGF-1 of 123 
 
±
 
 18% (
 
P
 
 
 
=
 
 0·02). GH 
 
<
 
 2 
 
µ
 
g/l,
normal IGF-1, or both were observed in 25 (70%), 24 (67%) and
21 (58%) patients, respectively. The mean reduction in tumour
volume was 43% (range 13–97%) and shrinkage 
 
>
 
 20% was obtained
in 21 patients (72%). SSTa treatment was well tolerated with few
digestive or metabolic side-effects.
 
Conclusion 
 
Long-term (up to 18 years) treatment with SSTa used
as ﬁrst-line therapy is effective from both an antihormonal and anti-
tumour perspective, and is well tolerated in acromegalic patients.
(Received 12 November 2006; returned for revision 4 January 2007; 
 
ﬁnally revised 17 February 2007; accepted 28 February 2007)
 
Introduction
 
Acromegaly is a chronic disease due to a hypersecretion of GH and
IGF-1, associated with an increase in mortality and morbidity,
mainly through cardiovascular, metabolic and neoplasic complica-
tions.
 
1
 
 The increased morbidity and mortality is directly related to
the control of the disease.
 
2
 
 The aim of treatment is to restore physio-
logical secretion of GH and IGF-1 or at least limit the GH/IGF-1
secretion excess, in order to reduce morbidity or mortality.
According to most guidelines, a neurosurgical approach is
considered as the ﬁrst-line treatment of acromegalic patients because
it is able to cure the acromegaly quickly and deﬁnitively.
 
3,4
 
 The results
vary according to the volume of the adenoma, the initial levels of
GH and the neurosurgeon’s experience.
 
5
 
 In cases of GH-secreting
microadenoma, the cure rate is 80% in the best series; in cases of
macroadenoma a cure rate of 50% is achieved, but the rate is much
lower if the adenoma is invasive.
 
6
 
 A second-line treatment is then
necessary.
Conventional
 
7
 
 or stereotaxic radiotherapy
 
8,9
 
 is sometimes used in
the treatment of acromegaly, but its efﬁcacy is delayed and the side-
effects can limit its use.
Medical treatment of acromegaly, frequently indicated as second-
line therapy, is based mainly on somatostatin analogues (SSTa), for
which the development of slow-release forms has simpliﬁed their use
and improved compliance.
 
10–12
 
 SSTa are discussed as primary treatment
when surgery is contraindicated or refused by the patient, and in
patients with normal magnetic resonance imaging (MRI). The medical
treatment also includes dopamine agonists with more modest effects
on GH secretion,
 
13
 
 and more recently a GH receptor antagonist
(pegvisomant) was developed, although its place in the therapeutic
armamentarium still remains to be deﬁned more precisely.
 
14
 
The aim of the present clinical study was to evaluate the long-term
antihormonal and antitumour efﬁcacy as well as the safety of SSTa
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in a cohort of acromegalic patients responsive to SSTa and primarily
treated with SSTa for a mean duration of 8 years (range 3–18 years).
 
Materials and method
 
Patients
 
Among the patients monitored in our centre from 1986 to 2003
(
 
n
 
 
 
=
 
 106) for the treatment of acromegaly, only patients treated with
SSTa as primary treatment for at least 3 years were included in this
clinical study. Sixty-nine patients treated by surgery or radiotherapy
were excluded: 39 patients had primary surgery and 22 had second-
ary surgery when GH/IGF-1 hypersecretion was uncontrolled by
SSTa (
 
n
 
 
 
=
 
 6), dopamine agonists (
 
n
 
 
 
=
 
 7) or their combination (
 
n
 
 
 
=
 
 9).
Pituitary radiotherapy was performed in primary (
 
n
 
 
 
=
 
 1) or after
pituitary surgery (
 
n
 
 
 
=
 
 26). One acromegalic patient had normal GH/
IGF-1 function after an acute episode of pituitary apoplexy.
The cohort included 17 men and 19 women with a mean age of
53 
 
±
 
 2·5 years (range 17–75) (Table 1). The biological diagnosis of
acromegaly was based on a plasma GH concentration 
 
>
 
 1 
 
µ
 
g/l after
oral administration of 75 g glucose, in association with a raised IGF-
1 concentration for age and sex. Primary medical therapy with SSTa
was initiated because of systemic complications that contraindicated
surgery (
 
n
 
 
 
=
 
 7), refusal by the patient to undergo surgery (
 
n
 
 
 
=
 
 8),
Table 1. Patient characteristics, duration of treatment, GH and IGF-1 levels at diagnosis and at the last evaluation during long-term somatostatin analogue 
treatment
Patient Sex
Age at
diagnosis
Duration of
treatment
(years)
Status of
adenoma
Initial GH
(ng/ml)
Final GH
(ng/ml)
Initial IGF-1
(% ULN)
Final IGF-1 
(% ULN)
1F 6 1 12 Macro 6 0·5 284 97
2M 6 1 8 M a c r o 6·8 0·2 286 95
3M 5 1 8 M icro 6·3 0·3 341 96
4M 5 6 8 M a c r o 2·5 0·8 445 274
5F 5 4 13 Macro 7 0·5 128 82
6F 5 2 5 M a c r o 2·5 0·8 247 247
7M 6 8 3 M a c r o 82 9·3 749 301
8F 3 8 3 M a c r o 2·5 4 203 206
9F 5 7 4 E S 8 0·8 167 95
10 F 45 3 Macro 35 10·6 234 217
11 M 17 10 Macro 6 0·3 116 40
12 F 63 5 ES 8 0·6 263 82
13 F 68 5 Macro 20 1 424 90
14 F 41 3 Macro 75 10 278 288
15 F 45 12 Micro 3·3 0·3 197 80
16 F 65 13 Macro 8·2 1·7 – 46
17 F 75 4 Macro 4·5 3·7 417 99
18 F 71 6 Macro 5·5 2 247 100
19 M 43 5 Macro 6·5 0·7 249 42
20 M 45 18 Micro – 2 614 161
21 M 67 9 Macro 15 2 – 59
22 M 66 12 Macro 10 2·7 – 192
23 F 21 17 Macro 28 0·3 – 54
24 F 63 10 Micro 2·5 0·3 287 83
25 M 70 3 Macro 3·6 2·7 191 193
26 F 52 8 ES 2 0·3 353 100
27 M 28 10 Macro 16·2 2·1 247 153
28 M 28 3 Micro 14·5 3·1 – 84
29 M 57 4 Macro 14 2·2 307 200
30 F 74 3 Micro 9 3·8 56 57
31 M 42 16 Micro 6·2 1 – 91
32 M 49 7 Macro 4·4 1·8 358 163
33 F 62 12 Macro 5·3 1·8 341 100
34 M 41 4 Macro 40 0·8 526 98
35 F 70 3 Macro 2·9 1·4 254 88
36 M 62 11 Micro 3·5 1 262 92
Mean ± SEM 53 ± 2·5 7·8 ± 0·7 13·5 ± 3·1 2·7 ± 0·7 302 ± 26 126 ± 12
M, male; F, female; Macro, macroadenoma; Micro, microadenoma; ES, empty sella turcica. 
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empty sella turcica (
 
n
 
 
 
=
 
 3) or invasive pituitary macroadenoma after
radiological evaluation (
 
n
 
 
 
=
 
  18). The initial pituitary imaging
revealed a macroadenoma in 25 patients, a microadenoma in eight
patients and an empty sella turcica in three patients. Six patients had
hyperprolactinaemia (
 
>
 
 20 
 
µ
 
g/l) at the time of the diagnosis. The
mean follow-up was 8 years (range 3–18).
The patients were assessed clinically for efﬁcacy and safety, bio-
logically and radiologically at the time of the diagnosis, 6 months
after starting SSTa therapy and subsequently annually.
 
Therapeutic protocol
 
In accordance with the protocol of the study, all patients were treated
with SSTa initially and throughout the duration of the study. The
treatments evolved over time and were as follows:
•N ineteen patients were initially treated with octreotide subcuta-
neously with a dosage between 300 and 1500 
 
µ
 
g/day (Sandostatin
 
®
 
,
Novartis Pharma, Rueil-Malmaison, France), 14 were switched to
lanreotide Autogel, 60 and 120 mg/28 days (Somatuline Autogel
 
®
 
,
Beaufour Ipsen, Paris, France) and one to octreotide LAR, 30 mg/
28 days (Sandostatin LAR
 
®
 
 Novartis Pharma) to improve compli-
ance to treatment and quality of life.
•T welve patients were initially treated with lanreotide Autogel,
60 mg/28 days, and the treatment was changed to octreotide LAR,
between 20 and 30 mg/28 days, in three patients because of transient
gastrointestinal symptoms or induration at the injection site.
•F ive patients were initially treated with octreotide LAR, 20 mg/
28  days, and the treatment was changed to lanreotide Autogel,
between 90 and 120 mg/28 days, in three patients because of tech-
nical problems with the injections.
The dosage of SSTa was adapted according to the hormonal response,
and for the slow-release formulations reassessed after the fourth
injection. In the case of insufﬁcient response (GH 
 
>
 
 2 
 
µ
 
g/l and/or
IGF-1 not normalized), treatment was increased to the maximal dose
(30 mg/28 days for octreotide LAR, 120 mg/28 days for lanreotide
Autogel).
In addition, some patients received treatment with dopamine ago-
nists during the study. In the six patients with hyperprolactinaemia,
treatment with dopamine agonists was initiated at diagnosis and was
as follows: bromocriptine 5–15 mg/day in two patients (Parlodel
 
®
 
,
Novartis Pharma); quinagolide 75–150 
 
µ
 
g/day in three patients
(Norprolac
 
®
 
, Ferring, Gentilly, France); and cabergoline 1 mg/week
in one patient (Dostinex
 
®
 
,  Pﬁzer, Paris, France). In nine other
patients, dopamine agonist treatment was initiated later to improve
GH/IGF-1 control and distributed as follows: bromocriptine 5 mg/
day in one patient, quinagolide 75–150 
 
µ
 
g/day in seven patients, and
cabergoline 3·5 mg/week in one patient.
 
Hormonal data
 
For the patients treated with slow-release formulations of SSTa
(Somatuline Autogel, Octreotide LAR), the hormonal assessment
was carried out on the day before the injection.
At each visit, the serum GH level was calculated as the average of
six successive GH samples, taken at 30-min intervals between 0900
and 1200 h. Before 2003, GH assays were performed using a radio-
immunometric technique (Cisbio international, Schering, Bagnols sur
Cèze, France). The detection limit was 0·02 
 
µ
 
g/l; the intra- and interassay
coefﬁcients of variation (CVs) were 2·1% and 4·5%, respectively. From
2003, GH assays have been performed using a chemiluminescence
technique (Nichols Institute Diagnostics, San Clemente, CA). The
detection limit is 0·02 
 
µ
 
g/l; the intra- and interassay CVs are 3·7% and
6·2%, respectively. With this assay, 3 mU/l corresponds to 1 
 
µ
 
g/l.
The rate of correlation between these two methods is as follows:
(
 
r
 
) 
 
=
 
 0·9269 with a regression formula 
 
y
 
 
 
=
 
 0·9127
 
x
 
 – 0·4601, obtained
from a linear regression analysis of the data.
At each visit, the IGF-1 level was assessed from a serum sample.
Before 2003, the IGF-1 assay used a radioimmunometric technique
(Diagnostic System Laboratories, Webster, TX). The detection limit
was 0·8 
 
µ
 
g/l; the intra- and interassay CVs were 1·5% and 3·7%,
respectively. From 2003, the IGF-1 assay used a chemiluminescence
technique (Nichols Institute Diagnostics). The detection limit is
6 
 
µ
 
g/l; the intra- and interassay CVs are 5·2% and 5·7%, respectively.
The rate of correlation between these two methods is as follows:
(
 
r
 
) 
 
=
 
 0·8819 with a regression formula 
 
y
 
 
 
=
 
 0·882
 
x 
 
– 19·84, obtained
from a linear regression analysis of the data.
The serum levels of PRL, TSH, T4, LH, FSH and testosterone were
measured using commercial methods.
 
Radiological data
 
The patients were evaluated at the time of the diagnosis, after
6 months of medical treatment and every year during the long-term
follow-up. Most of the neuroradiological data were obtained by MRI.
Some data – older or in the case of contraindication to MRI – were
obtained by computed tomography (CT) scan. All the images were
viewed by the same neuroradiologist (F.L.-L.), who was unaware of
the therapeutic protocol followed by the patient. Adenoma volume
was assessed by the Di Chiro formula:
 
15
 
 volume 
 
=
 
 
 
π
 
/6 
 
× 
 
(transverse
 
×
 
 anteroposterior 
 
×
 
 ventral). The MRI shots (Siemens Magneton;
1 T, Erlanger, Germany) were carried out in the coronal and sagittal
planes of 3 mm thickness, T1 weighed SE before and after injection
of gadolinium. The scanographic shots (Siemens Somaton Plus 4)
were carried out in the coronal and sagittal planes, millimetrically.
The radiological data were analysable in 29 of the 36 patients; an
empty sella turcica was evident in three patients and initial radio-
logical data were not available in four patients.
A gall bladder ultrasound was carried out upon diagnosis, after
6 months, and then annually.
 
Statistical data
 
Means are given with their standard error (SE). In the event of non-
normal distribution of the continuous variables, the median and the
interquartile range are presented. Comparisons of percentages were
made using the Pearson 
 
χ
 
2
 
-test. Means were compared using the
Student or Mann–Whitney tests (case of 2 means) and an analysis of
variance or the Kruskal–Wallis test (case of more than 2 means).
Nonparametric tests were used when the variables were not distrib-
uted normally or in the event of heterogeneity of variances. The per-
centage of variation in the size of the adenoma between diagnosis
and the last assessment was calculated in accordance with the 
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following formula: [(size
 
diagnosis
 
 – size
 
end
 
)/size
 
diagnosis
 
] 
 
×
 
 100. The cumu-
lative rate of patients controlled for GH or IGF-1 based on time were
estimated using the Kaplan–Meier method. Associations between the
different prognostic factors and the control of GH, IGF-1 or both
were sought in a survival analysis using the log rank test or, for
continuous variables, using the Cox proportional hazards model.
The data were analysed using STATA 7·0 software (Stata Corporation,
TX).
 
Results
 
Hormonal efficacy
 
Figure 1 shows the decrease in GH and IGF-1 concentrations during
primary treatment with SSTa in this cohort of acromegalic patients.
The mean (
 
±
 
 SEM) pretreatment GH level was 13·5 
 
±
 
 3·1 
 
µ
 
g/l (Table 1),
decreasing rapidly at 6 months to 3·8 
 
±
 
 0·8 
 
µg/l and to 2·4 ± 0·3 µg/l
(P < 0·01) at 1 year. The GH level decreased slowly over the course of
monitoring and was 1·6 ± 0·1 µg/l at 10 years (P = 0·02). The mean
pretreatment IGF-1 level was 302 ± 26% (expressed as a percentage
of the upper limit of the normal range matched for sex and age)
(Table 1), decreasing to 181 ± 14% at 6 months, to 174 ± 14% after
1 year (P < 0·01), and to 124 ± 18% after 10 years (P = 0·02).
Figure 2 shows a progressive increase in the rate of GH control
(< 2 µg/l) in a Kaplan–Meier analysis (survival analysis), with 41%
controlled at 1 year, 60% at 5 years, and 80% at 10 and 15 years.
A progressive increased rate of IGF-1 normalization can be noted,
with 17% controlled at 1 year, 31% at 5 years, 57% at 10 years and
87% at 15 years.
In this cohort of acromegalic patients, a GH level < 2 µg/l was
obtained in 25 of the 36 patients (70%), a normal IGF-1 level in 24
of the 36 patients (67%), and a GH level < 2 µg/l in combination
with a normal IGF-1 level in 21 of the 36 patients (58%). No
tachyphylaxis was observed during the long-term SSTa treatment.
Furthermore, there was no inﬂuence of age or sex on the hormonal
efﬁcacy observed during the SSTa treatment.
In  hyperprolactinaemic patients treated with SSTa and a
dopamine agonist as ﬁrst-line therapy (n = 6), the mean pretreat-
ment GH level was 12·5 ± 2·6 µg/l, decreasing to 3·7 ± 0·9 µg/l at
1 year, and the average pretherapeutic IGF-1 level was 253 ± 35%,
decreasing to 212 ± 23% at 1 year.
Fig. 1 Changes in GH ( ) and IGF-1 ( ) levels in 
acromegalic patients treated with SSTa (mean ± SE).
Fig. 2 Kaplan–Meier curves: the continuous line represents the level of 
control of GH. The broken line represents the level of normalization of 
IGF-1. The bold line represents the control of GH and IGF-1.286 J. C. Maiza et al.
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Concerning the subgroup of patients treated with dopamine ago-
nists as second-line therapy (n = 9), there was no further signiﬁcant
decrease in GH or IGF-1 level observed with SSTa alone (Table 2).
Tumour control
Of the 29 patients analysed, a shrinkage of more than 20% was
observed in 21 patients (72%). Figure 3 shows the variation in ade-
noma volume for each patient. An increase in tumour size was noted
in one patient (+13%) without local compressive phenomena while
GH/IGF-1 secretion was controlled (mean GH level  = 1·49 µg/l,
IGF-1 = 98%). The mean reduction in tumour size after 4 years of
SSTa treatment was 37%, and 43% (between +13 and –97%) at the
last measurement. There was no correlation between the reduction
in tumour volume and hormonal control observed during treatment
with SSTa. Finally, additional treatment with a dopamine agonist had
no beneﬁt in terms of tumour volume reduction (Table 2) in patients
primarily treated with SSTa.
Safety
Glucose metabolism. Impaired fasting glucose is deﬁned as a fasting
glycaemia > 1·10 g/l. Diabetes mellitus is deﬁned when a fasting
glycaemia > 1·26 g/l, according to the criteria of the World Health
Organization.
Before any treatment, 30 out of 36 patients did not present with
glucose metabolism abnormalities, two patients presented with an
impaired fasting glucose, and four patients had diabetes mellitus.
During the long-term treatment with SSTa, the mean glycosylated
haemoglobin level remained stable at 6·6 ± 0·3% upon diagnosis,
6·8 ± 0·6% at 5 years, and 6·3 ± 0·36% at 10 years. However, on in-
dividual follow-up, four patients developed an impaired glucose
tolerance, and four others diabetes mellitus. Conversely, one patient
with an impaired glucose tolerance became normoglycaemic.
Gall bladder lithiasis. During the course of the study and with
systematic evaluation, 13 patients out of 36 (36%) developed sludge
and/or gall bladder lithiasis. No patient presented any symptoms in
relation to these biliary abnormalities that required treatment to be
stopped or a cholecystectomy. The gall bladder lithiasis and/or sludge
appeared mainly at the beginning of treatment, within the 4 ﬁrst
years, with the exception of one case of sludge appearing after
10 years of treatment.
Pituitary function. At the time of diagnosis, four patients presented
with pituitary insufﬁciency: one isolated gonadotrophin insufﬁciency
(n = 1), one gonadotrophin and thyrotrophin insufﬁciencies (n = 1),
and two patients with corticotrophin, gonadotrophin and thyro-
trophin insufﬁciencies. No patient presented with a recovery of these
pituitary insufﬁciencies during the SSTa treatment. During the
Table 2. Hormonal and tumour volume changes in the subgroup of patients 
treated with dopamine agonists as second-line therapy, after 1 year of 
treatment (n = 9)
GH
(µg/l)
IGF-1
(% value over norm)
Tumour volume 
(mm
3)
Before treatment 4·1 ± 0·9 271 ± 32 4328 ± 1103
After treatment 5·0 ± 1·3 227 ± 16 3196 ± 1114
P < 0·26 < 0·11 < 0·83
Fig. 3 Individual evolution of the tumour volume in acromegalics treated with SSTa. The lined zone represents the ‘gain’ in reduction of volume in patients 
treated with dopamine agonist. Note that in two patients, the zone is lined in its entirety because the dopamine agonist was introduced at the same time as 
the SSTa treatment. The asterisk corresponds to microadenomas. The table summarizes the SSTa treatment followed by each patient.Primary SSTa therapy in acromegaly 287
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hormonal monitoring, one patient out of the remaining 32 patients
developed an isolated thyrotrophin insufﬁciency (3%).
Discussion
Treatment of acromegaly aims to keep the secretion of GH and
IGF-1 below the thresholds for disease-associated complications,
and to reduce the adenoma volume (or limit its expansion) to pre-
vent local compression phenomena and notably optic chiasma. The
treatment must be effective and well tolerated to enable satisfactory
observance. Finally, the pharmacoeconomic concerns must also be
considered.
The aim of this clinical study was to evaluate the long-term efﬁcacy
and tolerance of SSTa in a cohort of 36 acromegalic patients respon-
sive to this therapy, when this medical treatment was used as ﬁrst-
line therapy, for an average period of 8 years and with a maximum
of 18 years.
In this cohort of acromegalic patients treated with SSTa as ﬁrst-
line therapy, GH control (< 2 µg/l) was obtained in 70% of patients,
normal IGF-1 (value adjusted for sex and age) in 67%, and both GH
and IGF-1 control in 58%. These results are comparable with the data
in the literature reported in Table 3
16–23 and in recent meta-analyses.
24,25
A rapid and signiﬁcant reduction in the levels of GH and IGF-1 was
noted over the ﬁrst year of treatment, demonstrating the patients’
response to the SSTa and enabling this therapeutic class to be pur-
sued. Furthermore, there was no tachyphylaxis during the long-term
treatment with SSTa of these acromegalic patients. Finally, an
increase in GH and IGF-1 control was observed during long-term
treatment with SSTa. Several hypotheses can be put forward: a cumu-
lative effect of SSTa concentration over time, an increase in hormonal
efﬁcacy of the treatment as reported after the reduction in adenoma
volume by surgical debulking,
26,27 although there was no signiﬁcant
correlation between hormonal control and the change in adenoma
volume, or a change in the expression of the SST receptor subtypes
on the adenoma cells. Nevertheless, the results of the study conﬁrm
that SSTa therapy is associated with long-term control of GH/IGF-1
hypersecretion in such patients with acromegaly.
In some acromegalic patients, the addition of a dopamine agonist
did not offer better control of GH/IGF-1 hypersecretion than that
obtained during the initial treatment with SSTa. A greater anti-
hormonal efﬁcacy of treatment with dopamine agonists has been
observed in the event of a moderate increase in the levels of GH and
IGF-1. In such patients, combined dopamine agonist and SSTa treat-
ment offers an additional reduction in the levels of GH and IGF-1
in patients partially responsive to SSTa alone.
28 It should be noted
that  in vitro  studies on GH-adenoma cells of patients partially
responsive to SSTa treatment demonstrate that the effect of the SST-
DA (BIM23A387) chimeras is mainly linked to the pharmacological
effect on the dopamine site.
29,30  Therefore, in patients partially
responsive to SSTa used as ﬁrst-line therapy, several options can be
discussed to optimize hormonal control: the addition of a dopamine
agonist in case of associated hyperprolactinaemia or when GH/IGF-
1 hypersecretion is moderate,
31 surgical debulking in the case of
signiﬁcant adenoma volume,
26,27 or the addition of pegvisomant
(Somavert
®) on a weekly basis as was proposed recently.
32,33
Concerning efﬁcacy in relation to tumour size, the mean reduc-
tion in adenoma volume was 37% after 4 years and 43% at the last
measurement during long-term SSTa treatment, comparable to the
results reported in recent meta-analyses,
24,34 and 72% of patients
presented an adenoma volume reduction greater than 20%. A moderate
increase in tumour mass was noted in one patient with an enclosed
macroadenoma, although this increase in size did not lead to a local
mass effect, as the adenoma remained separate from the optic
chiasma. This patient was controlled on hormonal evaluation. An
increase in adenoma volume was reported in 3% of patients on SSTa
treatment, while a reduction in tumour volume (between 10% and
25%) was observed in 42% of patients on SSTa therapy in a recent
meta-analysis.
34 The greater efﬁcacy observed in our patients prob-
ably relates to the long-term SSTa treatment, and to the fact that the
patients had a ﬁrst-line medical therapy and therefore had not been
treated with radiotherapy or surgery, which can lead to periadeno-
matous ﬁbrosis, reducing the antitumour beneﬁt of the medical
treatment.
25  Furthermore, there was no signiﬁcant correlation
between the reduction in tumour volume and the antihormonal
Table 3. Comparison of the results observed in our cohort and in the main studies in the literature
Study Year
Duration
of study
(months)
No. of
patients
% GH
control
% IGF-1
control
% GH 
and IGF-1 
control
DEF shrinkage/
% shrinkage (n)
Mean
decreased
volume Diarrhoea Lithiasis
Lundin et al.
16 1997 34 18 NA NA NA ⇓ Vol > 18/72 (11) 51 (26–67) NA NA
Baldelli et al.
17 2000 24 118 77 63 NA ⇓ Vol > 20/22 (23) NA 46 12
Colao et al.
18 2001 24 36 71 68 NA ⇓ Vol > 25/80 (15) 53 (18–100) 28 8
Ayuk et al.
19 2002 41 22 36 67 NA NA NA NA 23
Bevan et al.
20 2002 6 27 79 53 50 ⇓ Vol > 10/96 (27) 49 (12–73) NA 26
Amato et al.
21 2002 24 20 35 45 NA ⇓ Vol > 10/95 (20) 28 NA NA
Cozzi et al.
22 2003 30 110 63 65 NA ⇓ Vol > 25/91 (11) NA 9 18
Cozzi et al.
23 2006 48 67 68·7 70·1 56·7 ⇓ Vol > 25/82 62 NA 12
This work 2006 96 36 70 67 58 ⇓ Vol > 20/72 43 30 36
NA, not available. The shrinkage was studied in the event of primary treatment (this is why the number of patients is lower than the total number in the 
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efﬁcacy of SSTa treatment in our study: we observed a signiﬁcant
reduction in GH and IGF-1 levels during the ﬁrst year whereas a
greater antitumour effect is observed after 4 years of treatment in
most patients. This dissociation could be linked to different mech-
anisms of the SSTa in the control of hormonal secretion and tumour
reduction.
35 In particular, the mechanisms of tumour volume reduc-
tion during SSTa therapy are still not fully elucidated, and a wide
variety of morphological changes have been reported.
36 Finally, in
most GH-secreting pituitary adenoma, regrowth has been reported
when SSTa were discontinued, indicating the need for long-term
treatment. Thus, long-term treatment with SSTa is associated with
tumour growth control in the majority of patients with GH-secreting
pituitary adenoma responsive to this treatment.
The tolerance of SSTa treatment is satisfactory and enables its
maintenance in acromegalic patients. During primary SSTa treat-
ment no patient stopped the medical therapy due to gastrointestinal,
cutaneous or metabolic side-effects. Among the side-effects of trans-
sphenoidal surgery, the risks of rhinorrhoea and meningitis are
estimated at 0·8% and 1·8%, respectively, the frequency of secondary
pituitary insufﬁciency is 1·8%, and that of perioperative mortality
is 0·1% in the best series.
6 Complications of surgery have been closely
linked to the experience of the neurosurgical team, so a well-trained
team is necessary.
5 Conventional radiotherapy has several disadvan-
tages, including secondary pituitary insufﬁciency occurring in up
to 80% after 10 years;
7 this complication seems to be less frequent
with stereotaxic radiotherapy, but long-term studies are needed to
evaluate this treatment.
9 A signiﬁcant increase in cerebrovascular
mortality,
37 as well as rare radioinduced cerebral tumours,
38 have
also been reported after conventional radiotherapy. During treatment
with SSTa, digestive symptoms such as diarrhoea and/or abdominal
pains decrease over time.
39 During systematic gall bladder ultra-
sound surveillance, a signiﬁcant frequency of lithiasis and/or sludge
can be noted (36% of cases in our study), in most patients during
the ﬁrst years of treatment, and they were asymptomatic in this
series. As suggested previously, it seems unnecessary to recommend
systematic ultrasound surveillance during long-term SSTa therapy.
40
At the metabolic level, mean HbA1C was stable over time, but in
eight patients their blood glucose levels deteriorated. Granulomas at
the injection site are rare with the use of slow-release forms of SSTa.
39
Finally, pituitary function was preserved in most cases except for the
onset of TSH insufﬁciency in one patient. Accordingly, long-term
SSTa treatment is well tolerated, but this medical treatment requires
monitoring of blood glucose levels to adapt antidiabetic treatment,
if necessary. However, SSTa treatment is associated with the main-
tenance of anterior pituitary function in most acromegalic patients.
In conclusion, this clinical study conﬁrms that long-term primary
treatment with SSTa is effective on an antihormonal and antitumour
level in patients with a GH-secreting pituitary adenoma responsive
to SSTa. The treatment is well tolerated and this enables its continued
use over the long term. Therefore, primary treatment with SSTa
seems to be a valued and validated addition to the therapeutic arma-
mentarium of acromegaly. It seems legitimate to indicate the use of
SSTa in the event of contraindication to surgery, refusal by the patient
to undergo surgery, normal pituitary MRI or empty sella turcica, and
when the success of surgery is unlikely, particularly in case of macro-
adenoma with large invasion of the cavernous sinus.
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